SCHEMBL6975182

SCHEMBL6975182

O=C(O)C1C=Nc2c(c(Cl)cc3cccnc23)C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
CCR1 P32246 1/20 0.40
CCR8 P51685 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.36
PLEC Q15149 1/20 0.36
PDE4D Q08499 3/20 0.35
PSD A5PKW4 1/20 0.35
PTPN6 P29350 1/20 0.35
PTPN11 Q06124 1/20 0.35
DOT1L Q8TEK3 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
RHEB Q15382 1/20 0.34
PDE4A P27815 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4B Q07343 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967454 0.86 L3MBTL1 (0.39) L3MBTL1ALDH1A1MAPT
SCHEMBL6987201 0.85 CCR1 (0.40) L3MBTL1CCR1CCR8ALDH1A1MAPT
SCHEMBL6984797 0.83 MAPK1 (0.38) L3MBTL1CCR1CCR8ALDH1A1MAPT
SCHEMBL965521 0.82 SLC40A1 (0.40) L3MBTL1ALDH1A1MAPTPDE4DSLC40A1
SCHEMBL1509799 0.78 SLC40A1 (0.37) L3MBTL1ALDH1A1MAPTPDE4DSLC40A1
SCHEMBL6985003 0.78 CCR1 (0.40) L3MBTL1CCR1CCR8ALDH1A1PSD
SCHEMBL1509598 0.77 LMNA (0.43) L3MBTL1CCR1CCR8ALDH1A1MAPT
SCHEMBL6981101 0.76 L3MBTL1 (0.43) L3MBTL1CCR1CCR8ALDH1A1MAPT
SCHEMBL6985131 0.75 KDM4E (0.37) L3MBTL1ALDH1A1MAPTMEN1KMT2A
SCHEMBL6985519 0.69 RELA (0.38) L3MBTL1ALDH1A1MAPTPDE4DSLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP claimed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US claimed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US claimed
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 L3MBTL1 2168/4885CCR1 245/4885CCR8 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.